Trial Profile
A Study to Assess and Compare the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Saxagliptin; Vildagliptin
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.
- 25 Sep 2013 Primary endpoint 'Dipeptidyl-peptidase-4-activity' has been met.
- 25 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.